Unusual T- and T/NK- cell non-Hodgkin's lymphoma of the larynx: A diagnostic challenge for clinicians and pathologists
โ Scribed by Johnny S. W. Mok; Martin Wai Pak; K. F. Chan; John Chow; C. A. van Hasselt
- Book ID
- 102235882
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 170 KB
- Volume
- 23
- Category
- Article
- ISSN
- 1043-3074
- DOI
- 10.1002/hed.1088
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
Lymphomas of t-cell and t/natural killer (t/nk)-cell types rarely involve the larynx. early symptoms are subtle and nonspecific, and confirmation of the diagnosis is often difficult. because of the rarity of this disease entity, the optimal management remains controversial.
Methods:
The case records of patients with the diagnosis of lymphoma involving the larynx were retrospectively reviewed. details of the pathologic condition, the difficulties in diagnosis, and treatment were presented.
Results:
One case of t-cell lymphoma (lennert's lymphoma subtype) and two cases of t/nk-cell lymphomas involving the larynx were presented. the diagnoses were all difficult to establish. all three patients received either multiagent chemotherapy or radiotherapy as the first-line treatment. they all died of the disease within 32 months of diagnosis.
Conclusions:
T- and t/nk-cell non-hodgkin's lymphoma of the larynx is a diagnostic challenge for clinicians and pathologists. conventional chemotherapy or radiotherapy has not been effective. a more aggressive therapy should be considered.
๐ SIMILAR VOLUMES
Fifty-five cases of non-Hodgkin's lymphoma (NHL) of the upper respiratory tract, comprising 27 sinonasal (SN) and 28 Waldeyer's ring (WR) NHL, were investigated for expression of Epstein-Barr virus (EBV)-encoded EBER transcripts and latent membrane protein-1 (LMP-1) by RNA in-situ hybridization (RIS
## Abstract Prognostic factors for longโterm survival of 312 patients with diffuse large cell or immunoblastic nonโHodgkin's lymphoma are presented based on analysis of the multiโinstitution clinicopathologic study sponsored by the National Cancer Institute. At the time of analysis, 75% of the pati